



Modern experimental and 
scientific data support the hy-
pothesis that immune-mediated 
inflammation is closely related to 
intestinal microbiota changes in 
celiac disease [1–3]. Celiac disease 
is a chronic genetically deter-
mined inflammatory disease, the 
target organ in which are entero-
cytes of the mucous membrane 
(MM) of the small intestine. 
The leading role in the develop-
ment of celiac disease is played 
by pathological autoimmune re-
actions that cause multisystem 
damage [4]. The relevance of the 
intestinal barrier dysfunction in 
the development of chronic in-
flammation of the small intestine 
has been repeatedly confirmed 
in scientific studies [5, 6]. The 
impairment MM’s permeabili-
ty is connected with inherited 
polymorphism of susceptibility 
genes (predispositions), such as 
MYO9B, PARD 3, MAGI2, DLG5 
(single nucleotide polymorphism 
R 30Q [rs1248696]) and PTPN 2 
[7, 8]. The role of pro-inflamma-
tory cytokines involved in the 
pathogenesis of celiac disease in 
modulating the composition of 
microbiota (IL-15), a decrease 
in the number of butyrate-pro-
ducing bacteria, is described. At 
the same time, the translocation 
of microorganisms promotes 
the activation of immune cells 
and enhances the production of 
cytokines, contributing to the 
chronicity of gastrointestinal in-
flammation. Intestinal dysbiosis 
in celiac disease is characterized 
by both taxonometric changes 
in the type of pro-inflammato-
ry dysbiosis and impaired inte-
gration of microbial metabolism 
with human metabolism – meta-
bolic dysbiosis [9]. It is important 
to note that these signs are deter-
mined both in primary patients 
and in patients on a gluten-free 
diet (GFD). In the first case, we 
can talk about the possible etio-
pathogenetic role of dysbiotic 
changes (primary dysbiosis), in 
the second – about secondary in-
testinal dysbiosis associated with 
a decrease in dietary fiber intake 
with a gluten-free diet [10, 11]. 
To modern date, about 200 me-
tabolites of microbial origin that 
can act as potential biomarkers 
of various diseases have been 
identified. The level of a number 
of metabolites in the blood and 
other biological fluids is largely 
determined by the metabolic ac-
tivity of the intestinal microbiota 
[12, 13]. Significant changes in 
the metabolism of blood, urine, 
feces and mucous membranes, 
ref lecting malabsorption, im-
paired energy metabolism, intes-
tinal microbiocenosis and intes-
tinal barrier were also detected 
in celiac disease.
Thus, disorders of microbial 
metabolism are a poorly studied 
problem, and the determination 
of specific microbial metabolites 
is of particular interest in the 
development of new methods for 
the diagnosis of celiac disease. 
Aim: to investigate a fecal 
microbiota composition and to 
identify candidate biomarkers of 
celiac disease (CD) by serum me-
tabolomics analysis. 
2. Materials and Methods
The study has been perform-
ing from 2015 to 2018 year on 
Department of Propaedeutics of 
internal diseases, gastroenter-
ology and dietoligy named af-
ter I. I. Rissa of North-Western 
State Medical University named 
after I. I. Mechnikov. Fresh fecal 
samples were collected from 43 
CD patients on a gluten-free diet 
and 42 healthy control (HC) pa-
tients. The characteristics of the 
object of study are presented in 
Table 1.
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Abstract: Aim: to investigate a fecal microbiota composition 
and to identify candidate biomarkers of celiac disease (CD) by 
serum metabolomics analysis.
Methods: the quantitative real-time polymerase chain reaction 
was used for fecal microbiota assessment. Serum metabolomic 
assays were conducted using the GC–MS. 
Results: serum of CD patients showed significant increases in 
stearic acid, 2-HIVA, succinate, fumarate and benzoate com-
pared to HC. A decrease in the level of eicosadiene and an in-
crease in AA in blood were determined. The ratio of AA to EDA 
was statistically significant (4.84 vs. 3.28, p=0.033). The elongase 
activity index in patients with celiac disease tended to increase 
(p=0.067). The colon microbiome in CD was characterized by 
decreasing in the level of butyrate-producing Faecalibacterium 
prausnitzii (F.p.) and Bifidobacterium spp.. Significant negative 
correlations were observed; between the levels of Bifidobacte-
rium spp. and F.p. and the concentration of succinic acid (rs= 
=–0.343 [p=0.026] and rs=–0.430 [p=0.005], respectively); the 
F.p. and the fumaric acid (r=–0.429, p=0.005); the benzoic acid 
and the amount of Bifidobacterium spp. (r=–0.341, p=0.025).
Conclusion: significant changes in serum levels of microbial and 
endogenous metabolites, reflecting some metabolic pathways 
disturbances were observed in CD. Metabolites and metabolo-
mic index reflecting the balance between pro-inflammatory and 
anti-inflammatory components, may be considered as candidate 
biomarkers of chronic inflammation and metabolic dysbiosis in 
CD. An increased B. fragilis/F.p. ratio can serve as available bio-
marker for intestinal pro-inflammatory dysbiosis in CD.
Keywords: butyrate, butyric acid, celiac disease, dysbiosis, Fae-
calibacterium prausnitzii, gut microbiota, serum metabolome, 
biomarkers, metabolomics.
Table 1
Characteristics of the main and control groups of the study 
Attribute CD HC
Number 43 42
Age 18–60 years 18–60 years
F/M ratio 1/1.5 1/1.5
GFD at least for the last 6 months –
Disease activity remission –
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All patients who participated in the study signed documents 
according with the ethical standards presented in the Helsinki 
Declaration of the World Medical Association “Recommen-
dations for Physicians Engaged in Biomedical Research with 
People” (2000).
The diagnosis of celiac disease was established on the basis 
of anamnesis, endoscopic, histomorphological and biochemical 
studies (morphometry of the mucous membrane of the retrob-
ulbar duodenum, HLA typing, immunological blood test) [14]. 
The study did not include patients undergoing acute infectious 
diseases, as well as taking any antibacterial, antiviral, antifun-
gal and antiprotozoal drugs, probiotics, prebiotics and drugs 
(dietary supplements) containing bacterial metabolites or their 
synthetic analogues, drugs with prokinetic activity in less than 
30 days before the start of the study. 
For fecal microbiota assessment, the quantitative real-time 
polymerase chain reaction (qRT-PCR) was used. Segregation 
(extraction) of DNA from evacuation samples was carried out in 
accordance with generally accepted standards [15]. To identify 
the group of butyrate-producing bacteria (BPB) by real-time 
PCR, the corresponding degenerate primers BCoATscrF (direct) 
and BCoATscrR (reverse) were used to amplify the butyryl-CoA 
gene: acetate-CoA transferase, the main enzyme responsible for 
the production of butyric acid by the microbiota of the colon. 
Serum metabolomic assays were conducted using the GC-MS 
(GCMS-QP2010 Plus, Shimadzu Corporation, Kyoto, Japan). 
The identification of low-molecular-weight compounds accord-
ing to GC–MS was performed using the international databases 
NIST 05, NIST 08, Human Metabolome Database (HMDB; 
http://www.hmdb.ca) and Serum Metabolome database (SMDB; 
http://www.serummetabolome.ca) [16, 17]. The data obtained 
during the chromatography-mass spectrometric studies were 
normalized to the content of heptadecanoic acid (C 17:0), select-
ed as the reference compound, the concentration of which was 
taken as 1 conventional unit.
Statistical data processing was performed using methods 
of the IBM SPSS Statistics 20 software (IBM Corp., USA). The 
normality of the data distribution was checked using the Kolm-
ogorov – Smirnov test, with the correction of the Lilliefors test 
and Shapiro – Wilk test. Due to the lack of a normal distribution 
of data, the median (Me) was used for the description, indicat-
ing the boundaries of the interquartile range, which are the 
25th (Q1) and 75th percentiles (Q3), respectively. Quantitative 
data were evaluated using nonparametric criteria: the Mann – 
Whitney U test and the Kolmogorov – Smirnov test. Hypothesis 
testing of the significance of differences between frequencies 
was conducted using the Fisher’s exact test. The information 
content of potential biomarkers was evaluated using a Receiver 
Operating Characteristic [ROC] Curve analysis. The critical 
value of the significance level (p) was taken equal to 0.05.
3. Results
93 compounds were identified: 28 metabolites – could have 
a double (endogenous + microbial) or predominantly microbial 
origin; for analysis, 37 metabolites are applicable. Selection 
criteria: 
1) metabolites of microbial origin; 
2) metabolites possibly associated with inflammatory and 
autoimmune intestinal pathologies; 
3) the most important endogenous metabolites (Krebs cycle, 
citric acid cycle).
Metabolites of the following groups were determined in 
blood serum: phenocarboxylic acids, hydroxycarboxylic acids, 
dicarboxylic and monocarboxylic acids. Only substances whose 
level change was statistically significant were included in the 
discussion.
Serum of CD patients showed significant increases in stearic 
acid, 2-hydroxyisovaleric acid (2-HIVA), succinate, fumarate 




Fig. 1. The concentration of acids in the blood serum of patients 
with celiac disease and healthy volunteers: a – phenocarboxylic 
acids; b – hydroxycarboxylic acids; c – dicarboxylic acids;  
PAA – phenylacetic acid; PHAA – parahydroxyphenyl acetic 
acid, 3-HCA – hydroxycinnamic acid,  
2HBA – 2-hydroxybutyric acid, 3HBA – 3-hydroxybutyric acid, 
2HIVA-2-hydroxyisovalerate acid
Changes in the concentration of monocarboxylic acids 
did not have statistical significance compared with healthy 
volunteers. A decrease in the level of eicosadiene and an in-
crease in arachidonic acids in blood included in the group of 
polyunsaturated fatty acids (ω-6-PUFA) were determined. In 
addition, a number of metabolic indices, biomarkers of fatty 
acid metabolism, were calculated. Thus, the level of increase in 
arachidonic acid (AA) in the blood of patients with celiac dis-
ease did not have significant differences with the control group 
(Fig. 2). However, the ratio of AA to eicosadienoic acid (EDA) 
(C20: 4n-6/C20:2n-6) was statistically significant (4.84 vs. 
3.28, p=0.033; Mann-Whitney U-test). The elongase activity 
index in patients with celiac disease tended to increase, but the 
differences were not statistically significant (p=0.067; Mann- 
Whitney U-test).
Analysis of feces microflora showed that the colon microbi-
ome of patients with celiac disease was characterized by a signif-
icant decrease in the level of butyrate-producing Faecalibacteri-
um prausnitzii and Bifidobacterium spp. compared with healthy 





















































































































































































































































































































teria, bacterial groups of Bacteroides fragilis, Lactobacillus and 
Escherichia coli did not have significant differences. Statistically 
significant changes in microbiocenosis were accompanied by 
deviations of indicators of metabolites of microbial origin in 
blood serum, which can be interpreted as signs of metabolic 
dysbiosis. Thus, significant negative correlations between the 
levels of representatives of probiotic bacteria – Bifidobacterium 
spp. and Faecalibacterium prausnitzii in feces and the concen-
tration of succinic acid in the blood serum (rs=–0.343 [p=0.026] 
and rs=–0.430 [p=0.005], respectively), as well as a significant 
negative correlation between the level of Faecalibacterium 
prausnitzii in feces and the concentration of fumaric acid in 
blood serum (r=–0.429, p=0.005), indirectly confirming the 
pro-inflammatory properties of succinate and fumarate. The 
level of benzoic acid was significantly reduced compared with 
the control group, and negatively correlated with the amount of 
Bifidobacterium spp. in feces (r=–0.341, p=0.025).
a
b
Fig. 2. The concentration of monocarboxylic acids in the blood 
serum of patients with celiac disease and healthy volunteers:  
a – the concentration of eicosadienoic and arachidonic acids;  
b – the concentration of palmitic, stearic and linoleic acids
3. Discussion and conclusions
Currently, carboxylic acids (food, microbial and endog-
enous origin) are considered as signalling molecules, regu-
latory and immunomodulation compounds in the human 
body. Mainly bacteroides and representatives of the clostrid-
ium genus produce phenocarboxylic acids, the increase of 
which was observed in patients with celiac disease. Therefore, 
Clostridium bifermentans, Clostridium difficile, Clostridium 
perfringens and Paeniclostridium sordellii are producers of 
phenylacetic acid, according to Intestinibacter bartlettii – PAA 
and PHPAA, and Clostridium sporogenes – phenylpropionic 
acid and parahydroxypropionic acid [18]. The latter, under-
going oxidation processes in the liver, become a substrate for 
the formation of benzoic acid. Benzoic and 3-hydroxyphenyl-
propionic acid are the most important microbial metabolite of 
caffeic acid, and are more common in patients with Clostrid-
ium difficile and Campylobacter jejuni infections [19]. The 
experimental results proved the role of phenylcarboxylic acids 
in inhibiting the growth of immune tissue of the spleen, liver 
and pancreas, which determines their pathogenetic role in 
the development of immune-mediated chronic diseases. The 
above makes it possible to use these acids as metabolic markers 
of pathologies accompanied by a disturbed immune response 
and chronic impaired microbial and endogenous metabolism, 
such as celiac disease. 
In the group of hydroxycarboxylic acids, a significant 
increase in 2HIVA, an intermediate in the ketogenesis and 
metabolism of valine, leucine and isoleucine, was noteworthy. 
The main producers of 2HIVA are Listeria spp., Eggerthella 
lenta and Prevotella, whose role in impaired intestinal barrier 
permeability increases with bacteraemia. Thus, the results 
obtained may be the result of increased bacterial production 
of 2HIVA because of intestinal microbiocenosis disorders. An 
increase in the concentration of hydroxycarboxylic acids in 
blood compared to the control group against the background 
of a decrease in the intestinal butyrate-producing bacteria Fae-
calibacterium prausnitzii indirectly indicates the involvement 
of this group of metabolites in the energy supply of colono-
cytes. A significant increase in the concentration of succinic 
acid was noted in blood of the examined patients, the main 
producers of which are Bacteroides spp., Eggerthella lenta, 
Paraprevotella clara, Paraprevotella xylaniphila, Marvinbry-
antia formatexigens, Ruminococcus champanellensis, En-
terococcus faecalis. During normal operation of the digestive 
tract, succinic and lactic acids are intermediate products of 
fermentation and do not accumulate in significant quantities, 
serving as co-substrates for the production of propionic and 
butyric acids. However, their number increases with intestinal 
dysfunctions and microbiota composition disorders, which 
contributes to the inflammatory process and allows their use 
as metabolic markers of inflammation. This circumstance is 
confirmed by the results of scientific studies, which proved 
that succinic acid is a pro-inflammatory signalling molecule 
that induces interleukin-1β via transcription factor 1α induced 
by hypoxia. In addition, we revealed significant negative 
correlations between the levels of representatives of probiotic 
bacteria in the feces (Bifidobacterium spp. and Faecalibacteri-
um prausnitzii) and the concentration of succinic acid in the 
blood serum (rs=–0.343 [p=0.026] and rs=–0.430 [p=0.005] 
respectively). 
The major part of circulating fatty (monocarboxylic) acids 
consists of palmitic, stearic, oleic, linoleic and arachidonic 
acids. Linoleic acid is the only essential fatty acid whose 
biological role is due to the participation in the synthesis of 
arachidonic acid and in the formation of phospholipids of cell 
membranes. A change in the concentration of monocarboxylic 
acids is observed not only in metabolic disorders, but also 
in diseases caused by chronic inflammation [20]. According 
to our data, an independent change in the concentration of 
monocarboxylic acids did not have statistically significant 
deviations in comparison with the parameters of the control 
group, which does not allow using them as specific markers 
of celiac disease. In this connection, the ratio AA to EDA was 
calculated, which determines the biotransformation of linoleic 
acid, as well as the balance between the pro-inflammatory 
and anti-inflammatory components of the pool of ω-6-PUFA, 
linoleic acid derivatives. The results of the study prove the 
possibility of using this index to assess the activity of chronic 
inflammation in the intestine. 
The course of inflammatory process in the intestine with 
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the development of significant metabolic disorders, with the 
involvement of other metabolically active organs and tissues 
(liver, mesenteric adipose tissue, central nervous system). An 
increased B. fragilis/F. prausnitzii ratio can serve as available 
biomarker for intestinal pro-inflammatory dysbiosis in CD. 
Altered metabolic pathways and individual metabolites, both 
endogenous and microbial, involved in these processes (suc-
cinate, fumarate, lactate, 2-hydroxybutyric, 2-hydroxyisova-
lerianic and other hydroxy acids, some phenylcarboxylic and 
indolecarboxylic acids) can serve as potential diagnostic tools 
(biomarkers) and/or therapeutic targets for celiac disease. Sig-
nificant changes in serum levels of microbial and endogenous 
metabolites, reflecting some metabolic pathways disturbances 
(glycolysis, TCA cycle, fatty acid metabolism, ketone body me-
tabolism, phenylalanine, tyrosine and tryptophan metabolism, 
microbial metabolism) are observed in CD. Some metabolites 
(e. g., a microbial metabolite 2-HIVA), as well as a new metab-
olomic index (AA/EDA ratio), reflecting the balance between 
pro-inflammatory and anti-inflammatory components of the 
omega-6 fatty acid pool, may be considered as candidate bio-
markers of chronic intestinal inflammation and metabolic 
dysbiosis in CD.
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